查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863423

血液和血浆成分市场按产品类型、应用、最终用户和分销管道划分－2025年至2032年全球预测

Blood & Plasma Components Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血液和血浆成分市场将成长至 725.5 亿美元，复合年增长率为 5.90%。

关键市场统计数据
基准年 2024 458.6亿美元
预计年份：2025年 486.2亿美元
预测年份 2032 725.5亿美元
复合年增长率 (%) 5.90%

本次培训重点在于影响医疗系统和产业领导者血液和血浆成分管理的临床、营运和商业性动态。

血液和血浆成分在现代医疗保健服务中发挥核心作用，为治疗通讯协定、诊断流程和生物医学研究提供支援。本导论概述了影响供应链和相关人员决策的核心临床和商业性因素。它整合了成分加工的最新进展、不断变化的法规环境以及不断变化的临床需求模式，为读者理解后续的分析章节奠定了基础。

临床医生和采购负责人面临临床需求与供应链限制之间错综复杂的相互作用。一方面，在多种适应症中，对血浆蛋白（例如免疫球蛋白和凝血因子）的治疗依赖性仍然很高。另一方面，从捐赠者招募和采集物流到低温运输管理和分销管道转型，营运压力要求各机构采取全面应对措施。本导言透过阐明关键的变革驱动因素，帮助领导者评估风险、优先考虑应对措施，并将投资与临床需求保持一致。

本节最后阐明了贯穿整个报告的分析方法：重点关注产品特定趋势、应用主导的使用模式、终端用户操作实践以及通路效能。这种想法清晰地引导读者理解后续的深入分析，使他们能够将洞见转化为战术性和策略行动，从而改善患者照护并提升组织韧性。

技术创新、不断变化的监管环境以及供应链多元化正在共同重塑血液和血浆生态系统的需求结构和韧性策略。

该产业正经历变革性的转变，相关人员管理供应、品质和商业策略的方式也随之改变。血浆分馏和病原体去除技术的进步提高了产品的安全性和保质期，而皮下注射剂型和重组替代疗法的创新则改变了治疗使用模式。同时，捐血互动和库存管理的数位化正在优化血液采集处理能力，减少废弃物，并建立更灵活的供应网络。这些技术主导的改进与临床实践的转变相辅相成，精准医疗和标靶治疗正在影响各个产品类型的需求结构。

政策法规的演变也在推动改变。监管机构正在实施更严格的药物监测要求，并针对血浆衍生产品製定新的指导方针，要求製造商和经销商在整个生命週期中加强监管。此外，地缘政治紧张局势和贸易政策调整更强调区域自主和采购多元化，迫使企业和医疗系统重新评估对单一供应商的依赖。因此，商业模式正在转向战略伙伴关係、扩大国内生产能力以及能够应对突发政策变化的灵活分销协议。

这些变化共同创造了一种环境，在这种环境中，敏捷性、技术应用和监管前瞻性是关键的差异化因素。那些投资于整合供应链视觉性、采用更安全、更有效率的加工技术并积极参与不断变化的法规结构的组织，将更有能力在满足临床需求的同时，维持成本效益和品质标准。

评估近期关税调整和贸易政策变化如何重塑血液和血浆成分筹资策略、区域生产决策和供应韧性。

近期关税和贸易政策的变化为血液和血浆成分的采购和分销策略带来了新的复杂性。影响进口原料、特殊试剂和成品血浆衍生产品的关税调整，加剧了供应商和医疗系统的成本压力，迫使采购团队重新评估采购区域和供应商合约。为此，许多机构正优先考虑供应链透明度和情境规划，以降低跨境成本波动带来的风险。

除了直接的成本影响外，关税变化也在影响製造商和经销商的策略行为。一些生产商正在加速生产区域化，并建立额外的加工中心，以避免与关税相关的摩擦，并维持进入关键市场的管道。作为应对，经销商正在使其库存多元化，并与医疗系统重新谈判合约条款，以共用风险并确保医疗服务的连续性。这些调整通常涉及长期商业性承诺和对本地低温运输基础设施的投资，虽然可以稳定供应，但也增加了资本密集度。

临床医生和医院营运团队正在感受到采购週期和库存管理政策的后续影响。由于相关人员将潜在的关税波动纳入库存和替代决策，计划週期有所延长，因此采购、临床和监管团队之间的协作对于维持治疗路径至关重要。最终，不断变化的关税环境凸显了製定多层次韧性策略的必要性，该策略结合了本地能力建设、灵活的分销模式和积极的监管应对措施，以保障患者获得治疗和临床连续性。

为市场参与企业提供基于深度细分的清晰讯息，将产品分类、临床应用、终端用户行为和分销管道与营运重点和商业性策略联繫起来。

细分市场分析揭示了产品、应用、终端用户和分销管道等各个维度上的微妙动态，每个维度都具有独特的营运和商业意义。根据产品类型，市场可细分为血浆蛋白、血小板、红血球和白血球。血浆蛋白本身需要更深入的分析。白蛋白在输液管理和加护治疗中发挥核心作用。由于凝血因子具有特定的治疗用途和生产方面的考虑，因此需要对凝血因子IX、凝血因子VIII和凝血酶原复合物浓缩物进行交叉分析。免疫球蛋白也可分为静脉注射和皮下注射两种给药方式，每种方式都有其独特的给药方法和供应需求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 人类血浆供应紧张导致对重组白蛋白替代品的需求增加。
  • 透过开发高免疫球蛋白疗法来增强对新兴感染疾病的被动免疫力
  • 扩大亚太地区的分馏产能，以满足日益增长的免疫球蛋白治疗需求
  • 在血液处理中采用病原体减少技术以提高输血安全标准
  • 为了提高捐血数量和效率，对连续血浆置换机的投资增加。
  • 血浆分馏生产商之间的整合日益加剧，正在重塑竞争格局和定价策略。
  • 转向分散式血库模式，并采用即时检测技术，以扩大遍远地区的血液供应。
  • 将人工智慧应用于预测捐血筛检和优化供应链
  • 重组凝血因子的出现减少了对血浆衍生浓缩物的依赖。
  • 引进一种新型病毒灭活方法，以解决血浆製品的安全问题。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的血液和血浆成分市场

  • 血浆蛋白
    • 白蛋白
    • 凝血因子
      • 因子九
      • 因子 VIII
      • 凝血酶原复合物浓缩物
    • 免疫球蛋白
      • 静脉注射免疫球蛋白
      • 皮下注射免疫球蛋白
  • 血小板
  • 红血球
  • 白血球

9. 按应用分類的血液和血浆成分市场

  • 诊断
  • 研究
  • 治疗用途

第十章 按最终用户分類的血液和血浆成分市场

  • 诊断实验室
  • 医院
    • 门诊手术中心
    • 公立医院
    • 私立医院
  • 研究所

11. 按分销管道分類的血液和血浆成分市场

  • 医院药房
  • 网路药房
  • 零售药房

12. 按地区分類的血液和血浆成分市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 按组别分類的血液和血浆成分市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国血液和血浆成分市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • CSL Limited
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Biotest AG
    • KEDRION SpA
    • Shanghai RAAS Blood Products Co., Ltd
    • Bio Products Laboratory Limited
    • LFB SA
    • Sanquin Blood Supply Foundation
Product Code: MRR-5C6F41F5AF8E

The Blood & Plasma Components Market is projected to grow by USD 72.55 billion at a CAGR of 5.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 45.86 billion
Estimated Year [2025] USD 48.62 billion
Forecast Year [2032] USD 72.55 billion
CAGR (%) 5.90%

A focused orientation to the clinical, operational, and commercial dynamics shaping blood and plasma component management for health systems and industry leaders

The blood and plasma components landscape occupies a central role in modern healthcare delivery, underpinning therapeutic protocols, diagnostic workflows, and biomedical research. This introduction frames the core clinical and commercial contours that influence supply chains and stakeholder decision-making. It synthesizes recent advances in component processing, the evolving regulatory environment, and shifting patterns of clinical demand, establishing a foundation for readers to interpret subsequent analytical chapters.

Clinicians and procurement leaders face a complex interplay of clinical need and supply chain constraints. On one hand, therapeutic reliance on plasma proteins such as immunoglobulins and coagulation factors remains high across diverse indications. On the other hand, operational pressures-ranging from donor recruitment and collection logistics to cold-chain management and distribution channel transformations-require integrated responses across institutions. By framing the primary vectors of change, this introduction prepares leaders to evaluate risk, prioritize resilience measures, and align investment with clinical imperatives.

The section closes by articulating the analytical approach used throughout the report: a focus on product-specific dynamics, application-driven utilization patterns, end-user operational realities, and distribution channel effectiveness. This orientation equips readers to follow the subsequent deep-dive analyses with clarity and to translate insights into tactical and strategic actions that enhance patient care and institutional robustness.

How technological innovation, regulatory evolution, and supply chain diversification are jointly reshaping demand profiles and resilience strategies across the blood and plasma ecosystem

The sector is experiencing transformative shifts that recalibrate how stakeholders manage supply, quality, and commercial strategy. Technological advances in plasma fractionation and pathogen reduction have improved product safety and shelf life, while innovations in subcutaneous delivery formats and recombinant alternatives are reshaping therapeutic use patterns. Concurrently, digitalization of donor engagement and inventory management is optimizing collection throughput and reducing waste, enabling more responsive supply networks. These technology-driven improvements are complemented by changes in clinical practice, where precision medicine and targeted therapeutics are influencing demand composition across product classes.

Policy and regulatory evolution also drives transformation. Regulators are deploying more rigorous pharmacovigilance expectations and novel guidance on plasma-derived products that demand closer lifecycle oversight from manufacturers and distributors. Moreover, geopolitical tensions and trade policy adjustments have increased the emphasis on regional self-reliance and diversified sourcing, prompting firms and health systems to reconsider single-supplier dependencies. As a result, commercial models are shifting toward strategic partnerships, domestic capacity expansion, and flexible distribution agreements that can withstand policy shocks.

Taken together, these shifts create an environment in which agility, technological adoption, and regulatory foresight become critical differentiators. Organizations that invest in integrated supply chain visibility, adopt safer and more efficient processing technologies, and proactively engage with evolving regulatory frameworks will be better positioned to meet clinical demand while maintaining cost-effectiveness and quality standards.

Assessing how recent tariff realignments and trade policy shifts are reconfiguring procurement strategies, regional production decisions, and supply resilience for blood and plasma inputs

Recent tariff measures and trade policy developments have introduced new layers of complexity into procurement and distribution strategies for blood and plasma components. Tariff adjustments affecting imported raw materials, specialized reagents, and finished plasma-derived products have increased cost pressure for suppliers and health systems, compelling procurement teams to reassess sourcing geographies and supplier agreements. In response, many organizations have prioritized supply chain transparency and scenario planning to mitigate exposure to cross-border cost volatility.

Beyond direct cost impacts, tariff shifts influence strategic behaviors among manufacturers and distributors. Some producers have accelerated regionalization of production and established additional processing hubs to circumvent tariff-related frictions and to maintain access to key markets. Distributors, in turn, have diversified inventory holdings and renegotiated contractual terms with health systems to share risk and preserve continuity of care. These adaptations often involve longer-term commercial commitments and investments in local cold-chain infrastructure, which can stabilize supply but may also raise capital intensity.

Clinicians and hospital operations teams feel the downstream effects in procurement cycles and inventory policies. Planning horizons have lengthened as stakeholders incorporate potential tariff disruptions into stocking and substitution decisions, and collaboration across procurement, clinical, and regulatory teams has become essential to maintain treatment pathways. Ultimately, the evolving tariff landscape underscores the need for multi-layered resilience strategies that combine local capacity building, flexible distribution models, and proactive regulatory engagement to safeguard patient access and clinical continuity.

Deep segmentation-driven clarity that links product classes, clinical applications, end-user behaviors, and distribution channels to operational priorities and commercial tactics for market participants

Segmentation analysis reveals nuanced dynamics across product, application, end-user, and distribution channel dimensions, each of which drives distinct operational and commercial implications. Based on product type, the market differentiates between plasma proteins, platelets, red blood cells, and white blood cells. Plasma proteins themselves require a deeper lens: albumin plays a central role in volume and critical care management; coagulation factors must be examined across Factor IX, Factor VIII, and prothrombin complex concentrates due to their specific therapeutic applications and manufacturing considerations; and immunoglobulins are split into intravenous and subcutaneous modalities, each with unique administration and supply requirements.

Based on application, diagnostic, research, and therapeutic uses produce divergent demand rhythms and regulatory expectations. Diagnostic consumption emphasizes consistent availability for laboratory workflows and reagent quality, research demand fluctuates with grant cycles and clinical trial activity, and therapeutic utilization follows clinical practice patterns and treatment protocol adoption. Based on end user, diagnostic laboratories, hospitals, and research institutions impose different procurement constraints and service expectations. Within hospitals, the spectrum includes ambulatory surgical centers, government hospitals, and private hospitals, each exhibiting distinct purchasing power, inventory practices, and clinical pathway integration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies vary in their fulfillment models, regulatory compliance requirements, and patient access touchpoints, affecting how products are delivered and managed at the point of care.

These segmentation lenses intersect to create complex value chains. For example, immunoglobulin demand in private hospitals delivered via hospital pharmacies requires different contracting and logistic arrangements than immunoglobulin for research supplied through online pharmacy channels. Recognizing these intersections enables more precise prioritization of investments in cold-chain capacity, formulation innovation, and channel-specific commercial tactics that align product attributes with end-user needs and distribution realities.

How regional regulatory diversity, infrastructure maturity, and distribution architectures across the Americas, Europe Middle East & Africa, and Asia-Pacific shape strategic market entry and operational design

Regional dynamics significantly condition strategic options for manufacturers, distributors, and healthcare providers. The Americas show a concentrated blend of advanced processing infrastructure, well-established donor programs, and mature reimbursement frameworks that favor rapid adoption of technological improvements and scalable distribution networks. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes, heterogeneous healthcare financing arrangements, and varying levels of domestic manufacturing capability, which together demand tailored regulatory strategies and selective investments in regional hub models to ensure supply continuity.

Asia-Pacific demonstrates rapid growth in healthcare infrastructure investment, expansion of domestic plasma collection capacity, and a rising emphasis on localized manufacturing to meet growing clinical demand. Within each region, differences in procurement sophistication, regulatory stringency, and distribution channel maturity influence how organizations design supply strategies and commercial partnerships. For instance, markets with advanced hospital pharmacy networks can deploy centralized inventory optimization tools, whereas regions with diverse retail and online channels may require omnichannel distribution strategies and enhanced cold-chain monitoring.

Taken together, regional insights underscore the importance of differentiated market entry approaches and adaptive operational models. Firms that calibrate their commercial propositions to regional regulatory landscapes, payer mechanisms, and distribution architectures will more effectively balance access, quality, and cost considerations across global footprints.

Profiles of industry players that combine manufacturing excellence, regulatory foresight, and distribution agility to secure clinical trust and operational resilience across product lines

Leading organizations within the sector demonstrate a convergence of capabilities that combine advanced manufacturing, integrated quality management, and strategic distribution partnerships. Companies that invest in modern fractionation and pathogen mitigation technologies secure both regulatory confidence and clinical trust, while those that emphasize supply chain transparency and digital inventory controls reduce waste and improve allocation precision. Strategic alliances between manufacturers and hospital networks facilitate demand forecasting and buffer management, enabling more responsive replenishment and reduced clinical disruption.

Competitive differentiation increasingly arises from portfolio breadth and modality flexibility. Firms offering varied formulations-such as both intravenous and subcutaneous immunoglobulins-and a portfolio that spans albumin and targeted coagulation factors, can better meet heterogeneous clinical needs. Additionally, companies that develop multi-channel distribution models, incorporating hospital pharmacies, online fulfillment, and retail partnerships, create more resilient access pathways for patients and providers. Effective companies also engage regulators proactively, collaborating on post-market surveillance and safety reporting to maintain product integrity and market trust.

Ultimately, the organizations that perform best combine technical excellence in processing with commercial agility and an ability to partner across the ecosystem. Their capabilities in manufacturing, regulatory navigation, and distribution orchestration position them to respond to shifting clinical protocols and supply chain pressures while maintaining patient safety.

Practical and strategic recommendations for executive teams to strengthen manufacturing safety, diversify supply networks, and enhance digital and regulatory capabilities for enduring resilience

Industry leaders should adopt a proactive stance that integrates technological investment, strategic partnerships, and operational resilience measures to navigate current complexities. First, accelerating deployment of advanced processing and pathogen-reduction technologies will improve product safety and reduce wastage, thereby strengthening clinical and regulatory confidence. Concurrently, investing in end-to-end digital visibility-from donor recruitment analytics through inventory and cold-chain monitoring-will enable more accurate demand forecasting and rapid response to supply disruptions.

Second, leaders must cultivate diversified supply strategies that blend regional production capacity, multi-supplier agreements, and flexible distribution arrangements tailored to hospital pharmacies, online fulfillment, and retail channels. These strategies should be coupled with contractual terms that share risk and incentivize service continuity. Third, proactive regulatory engagement is essential: companies and healthcare institutions should invest in dedicated regulatory intelligence and pharmacovigilance capabilities to anticipate policy shifts and to respond efficiently to safety queries.

Finally, close collaboration between manufacturers, clinical leaders, and procurement teams will translate strategic intent into operational reality. Joint scenario planning, shared KPIs for supply reliability, and periodic cross-functional reviews will align incentives and reduce the risk of treatment interruption. By implementing these measures, industry leaders can enhance patient access while managing cost and compliance imperatives.

A transparent and reproducible research approach combining expert interviews, regulatory and clinical literature review, and scenario analysis to ensure actionable and validated insights

The research methodology combines multi-source qualitative analysis, stakeholder interviews, and structured secondary research to build a rigorous and reproducible evidence base. Primary engagement included expert interviews with clinical leaders, procurement officers, supply chain managers, and regulatory specialists to capture real-world operational constraints and strategic priorities. These conversations informed thematic analyses and validated assumptions about product utilization patterns and channel behaviors.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, and publicly available clinical guidelines to triangulate findings and ensure alignment with current practice standards. The analytic process emphasized cross-validation: insights derived from interviews were compared against documented regulatory developments and clinical practice trends to reduce bias. In addition, scenario analyses were used to explore the implications of supply disruptions, trade policy shifts, and technology adoption, enabling robust recommendations that reflect plausible operational futures.

Throughout the methodology, emphasis was placed on transparency, reproducibility, and practical relevance. The result is a structured framework that links evidence to conclusions and that supports decision-makers in translating insights into targeted actions across procurement, clinical operations, and commercial strategy.

Strategic synthesis of clinical, operational, and commercial implications that underscores the urgency of coordinated modernization and resilience initiatives across the sector

The conclusion synthesizes the report's core implications for clinical, commercial, and operational stakeholders. The blood and plasma components arena is at a strategic inflection point where technological innovation, regulatory change, and supply chain reconfiguration intersect to redefine resilience and access. Organizations that prioritize investment in safer processing technologies, robust digital visibility, and diversified supply networks will be better equipped to absorb shocks and to maintain continuity of care for patients reliant on these critical therapies.

Moreover, the interplay of product segmentation, application-specific demand, and distribution channel dynamics requires coordinated cross-functional strategies. Procurement leaders, clinical directors, and manufacturing executives must align incentives and share real-time information to prevent shortages, optimize inventory, and support evidence-driven substitution where clinically appropriate. Regional strategies should reflect local regulatory regimes and distribution architectures, while commercial approaches must maintain flexibility to accommodate differing end-user needs.

In closing, success in this sector depends on marrying technical excellence with strategic adaptability. Stakeholders that act decisively to modernize operations, engage regulators proactively, and form resilient partnerships will secure both clinical reliability and competitive advantage in a dynamic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing demand for recombinant albumin alternatives driven by supply constraints in human plasma
  • 5.2. Development of hyperimmunoglobulin therapies targeting emerging infectious diseases to bolster passive immunity
  • 5.3. Expansion of fractionation capacity in Asia Pacific to meet rising demand for immunoglobulin therapies
  • 5.4. Adoption of pathogen reduction technologies in blood processing to enhance transfusion safety standards
  • 5.5. Growing investment in continuous flow plasmapheresis devices to improve donor throughput and efficiency
  • 5.6. Rising corporate consolidation among plasma fractionators reshaping competitive dynamics and pricing
  • 5.7. Shift towards decentralized blood banking models using point-of-care testing to expand rural accessibility
  • 5.8. Integration of artificial intelligence for predictive donor screening and supply chain optimization
  • 5.9. Emergence of recombinant coagulation factors reducing dependency on plasma-derived concentrates
  • 5.10. Implementation of novel viral inactivation methods to address safety concerns in plasma products

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood & Plasma Components Market, by Product Type

  • 8.1. Plasma Proteins
    • 8.1.1. Albumin
    • 8.1.2. Coagulation Factors
      • 8.1.2.1. Factor IX
      • 8.1.2.2. Factor VIII
      • 8.1.2.3. Prothrombin Complex Concentrates
    • 8.1.3. Immunoglobulins
      • 8.1.3.1. Intravenous Immunoglobulin
      • 8.1.3.2. Subcutaneous Immunoglobulin
  • 8.2. Platelets
  • 8.3. Red Blood Cells
  • 8.4. White Blood Cells

9. Blood & Plasma Components Market, by Application

  • 9.1. Diagnostic
  • 9.2. Research
  • 9.3. Therapeutic

10. Blood & Plasma Components Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
    • 10.2.1. Ambulatory Surgical Centers
    • 10.2.2. Government Hospitals
    • 10.2.3. Private Hospitals
  • 10.3. Research Institutions

11. Blood & Plasma Components Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Blood & Plasma Components Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood & Plasma Components Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood & Plasma Components Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. CSL Limited
    • 15.3.2. Grifols, S.A.
    • 15.3.3. Takeda Pharmaceutical Company Limited
    • 15.3.4. Octapharma AG
    • 15.3.5. Biotest AG
    • 15.3.6. KEDRION S.p.A.
    • 15.3.7. Shanghai RAAS Blood Products Co., Ltd
    • 15.3.8. Bio Products Laboratory Limited
    • 15.3.9. LFB S.A.
    • 15.3.10. Sanquin Blood Supply Foundation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD & PLASMA COMPONENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD & PLASMA COMPONENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD & PLASMA COMPONENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLATELETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY WHITE BLOOD CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD & PLASMA COMPONENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA BLOOD & PLASMA COMPONENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY PLASMA PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY COAGULATION FACTORS, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY IMMUNOGLOBULINS, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC BLOOD & PLASMA COMPONENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC BLOOD & P